Developed under the direction and sponsorship of AstraZeneca

Asthma Impairment and Risk Questionnaire (AIRQ®)

For use by health care providers with their patients 12 years and older who have been diagnosed with asthma. AIRQ® is intended to be part of an asthma clinic visit. Learn more by clicking About, above. Please answer all of the following questions.

About

Asthma Impairment and Risk Questionnaire (AIRQ®) Information for Health Care Providers


AIRQ® Intended Use and Instructions for Use

The AIRQ® is a patient assessment tool intended to help identify patients 12 years of age and older whose health may be at risk because of uncontrolled asthma. This assessment is based on a series of patient-facing questions about asthma medications, respiratory symptoms, and utilization of health care resources. Depending on the patient's responses to these questions, the patient will receive a score reflecting their level of asthma control. After completion of the AIRQ®, the patient and health care provider should discuss the responses to each of the individual questions, the total AIRQ® score, and the patient's level of asthma control, and form a treatment plan.

The AIRQ® is not intended to:

> Diagnose asthma
> Replace the advice or treatment of a health care provider
> Direct specific actions to treat, mitigate, or improve asthma
> Collect or store any laboratory values or lung function test values


Health Care Provider Instructions for Use

1. Provide your patient with the AIRQ® during or immediately prior to their appointment.
2. Examine the responses to each of the individual questions, the total AIRQ® score, and the patient's level of asthma control.
3. Discuss responses to each of the individual questions, the total AIRQ® score, and the patient's level of asthma control with your patient.
4. Determine a treatment plan with your patient based on the information you've learned during your discussion and clinical assessment of the patient, and through responses to the AIRQ® questions.


Information on the Validation and Interpretation of AIRQ®

1. AIRQ® is a 10-item, equally weighted, yes/no composite asthma control questionnaire that includes 7 impairment and 3 risk items.
2. The AIRQ® was validated against a standard of ACT™ score (impairment) + prior-year, chart-documented exacerbations (risk) in 442 patients 12 years of age and older who were previously diagnosed with asthma.
3. Multivariable logistic regression analyses were used to determine questions with the greatest validity in discriminating between patients of varying levels of control.
4. A total of 10 questions were identified for inclusion in the AIRQ®.
5. The AIRQ® performed well with respect to the ACT™ + exacerbations standard in identifying well-controlled vs not well-/very poorly controlled and well-/not well-controlled vs very poorly controlled asthma, with area under the receiver operating characteristic (ROC) curves of 0.94 and 0.93, respectively.
6. The combination of selected AIRQ® items and cut points of control demonstrated a sensitivity of 0.90 to identify patients whose asthma was well-controlled (cut point of ≥2), and a specificity of 0.96 to determine patients whose asthma was very poorly controlled (cut point of ≥5).
7. For further information on the development and cross-sectional validation of the AIRQ®, please refer to Murphy KR, et al. J Allergy Clin Immunol Pract. 2020;8(7):2263-2274.e5; and Murphy KR, et al. J Allergy Clin Immunol Pract. 2021;9(1):603.


References

Start implementing AIRQ® in your practice!

Use of AIRQ® in the clinical treatment of patients or for independent clinical study (not sponsored by a competitor of AstraZeneca) is free in perpetuity, however we do request that you contact our licensing partner, RWS, to register your practice as a user of AIRQ® by obtaining your free license. This gives us the ability to notify you if we ever make changes to AIRQ®.


Here are some guides to help you get started with AIRQ® in your practice:

AIRQ® implementation one-pager, for every kind of practice workflow
Instructions for implementing AIRQ® in Epic EMR
Instructions for implementing AIRQ® in Cerner EMR
Instructions for implementing AIRQ® in other digital platforms


And here are some resources to help you and your patients learn more!

The AIRQ® tool (downloadable and digital)
Resources for asthma care, including downloadable patient education, in both English and Spanish
Note: Patients must save as a PDF, or print their results from airqscore.com and bring it with them to the appointment; this site does not store any AIRQ® results or collect any patient-identifiable information whatsoever


Reference

For more information, please visit: Asthma Resource Center


Legal Notices and Disclaimer

*Medrol® (Pfizer, Inc.) or methylprednisolone.
The trademarks depicted above are the property of their respective owners.

1Global Strategy for Asthma Management and Prevention: ©2020 Global Initiative for Asthma

AIRQ® is a trademark of the AstraZeneca group of companies.

©2022 AstraZeneca. All rights reserved.
US-61581 Last Updated 4/22

1. In the past 2 weeks, has coughing, wheezing, shortness of breath, or chest tightness bothered you during the day on more than 4 days?

0/10 completed

About

Asthma Impairment and Risk Questionnaire (AIRQ®) Information for Health Care Providers


AIRQ® Intended Use and Instructions for Use

The AIRQ® is a patient assessment tool intended to help identify patients 12 years of age and older whose health may be at risk because of uncontrolled asthma. This assessment is based on a series of patient-facing questions about asthma medications, respiratory symptoms, and utilization of health care resources. Depending on the patient's responses to these questions, the patient will receive a score reflecting their level of asthma control. After completion of the AIRQ®, the patient and health care provider should discuss the responses to each of the individual questions, the total AIRQ® score, and the patient's level of asthma control, and form a treatment plan.

The AIRQ® is not intended to:

> Diagnose asthma
> Replace the advice or treatment of a health care provider
> Direct specific actions to treat, mitigate, or improve asthma
> Collect or store any laboratory values or lung function test values


Health Care Provider Instructions for Use

1. Provide your patient with the AIRQ® during or immediately prior to their appointment.
2. Examine the responses to each of the individual questions, the total AIRQ® score, and the patient's level of asthma control.
3. Discuss responses to each of the individual questions, the total AIRQ® score, and the patient's level of asthma control with your patient.
4. Determine a treatment plan with your patient based on the information you've learned during your discussion and clinical assessment of the patient, and through responses to the AIRQ® questions.


Information on the Validation and Interpretation of AIRQ®

1. AIRQ® is a 10-item, equally weighted, yes/no composite asthma control questionnaire that includes 7 impairment and 3 risk items.
2. The AIRQ® was validated against a standard of ACT™ score (impairment) + prior-year, chart-documented exacerbations (risk) in 442 patients 12 years of age and older who were previously diagnosed with asthma.
3. Multivariable logistic regression analyses were used to determine questions with the greatest validity in discriminating between patients of varying levels of control.
4. A total of 10 questions were identified for inclusion in the AIRQ®.
5. The AIRQ® performed well with respect to the ACT™ + exacerbations standard in identifying well-controlled vs not well-/very poorly controlled and well-/not well-controlled vs very poorly controlled asthma, with area under the receiver operating characteristic (ROC) curves of 0.94 and 0.93, respectively.
6. The combination of selected AIRQ® items and cut points of control demonstrated a sensitivity of 0.90 to identify patients whose asthma was well-controlled (cut point of ≥2), and a specificity of 0.96 to determine patients whose asthma was very poorly controlled (cut point of ≥5).
7. For further information on the development and cross-sectional validation of the AIRQ®, please refer to Murphy KR, et al. J Allergy Clin Immunol Pract. 2020;8(7):2263-2274.e5; and Murphy KR, et al. J Allergy Clin Immunol Pract. 2021;9(1):603.


References

Start implementing AIRQ® in your practice!

Use of AIRQ® in the clinical treatment of patients or for independent clinical study (not sponsored by a competitor of AstraZeneca) is free in perpetuity, however we do request that you contact our licensing partner, RWS, to register your practice as a user of AIRQ® by obtaining your free license. This gives us the ability to notify you if we ever make changes to AIRQ®.


Here are some guides to help you get started with AIRQ® in your practice:

AIRQ® implementation one-pager, for every kind of practice workflow
Instructions for implementing AIRQ® in Epic EMR
Instructions for implementing AIRQ® in Cerner EMR
Instructions for implementing AIRQ® in other digital platforms


And here are some resources to help you and your patients learn more!

The AIRQ® tool (downloadable and digital)
Resources for asthma care, including downloadable patient education, in both English and Spanish
Note: Patients must save as a PDF, or print their results from airqscore.com and bring it with them to the appointment; this site does not store any AIRQ® results or collect any patient-identifiable information whatsoever


Reference

For more information, please visit: Asthma Resource Center


Legal Notices and Disclaimer

*Medrol® (Pfizer, Inc.) or methylprednisolone.
The trademarks depicted above are the property of their respective owners.

1Global Strategy for Asthma Management and Prevention: ©2020 Global Initiative for Asthma

AIRQ® is a trademark of the AstraZeneca group of companies.

©2022 AstraZeneca. All rights reserved.
US-61759 Last Updated 4/22

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.